Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.49
MRK's Cash to Debt is ranked lower than
73% of the 778 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.15 vs. MRK: 0.49 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.49
0.32
2.45
Equity to Asset 0.45
MRK's Equity to Asset is ranked lower than
75% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.45
0.34
0.53
Interest Coverage 10.88
MRK's Interest Coverage is ranked lower than
71% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. MRK: 10.88 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 9.88 Max: 20.13
Current: 10.88
4.14
20.13
F-Score: 7
Z-Score: 3.43
M-Score: -2.68
WACC vs ROIC
6.50%
10.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.67
MRK's Operating margin (%) is ranked higher than
79% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.44 vs. MRK: 18.67 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 6.43  Med: 16.45 Max: 21.86
Current: 18.67
6.43
21.86
Net-margin (%) 13.01
MRK's Net-margin (%) is ranked higher than
75% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. MRK: 13.01 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.3 Max: 47.03
Current: 13.01
1.87
47.03
ROE (%) 11.46
MRK's ROE (%) is ranked higher than
65% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.76 vs. MRK: 11.46 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.51  Med: 14.91 Max: 42.27
Current: 11.46
1.51
42.27
ROA (%) 5.12
MRK's ROA (%) is ranked higher than
60% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. MRK: 5.12 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.5 Max: 16.34
Current: 5.12
0.79
16.34
ROC (Joel Greenblatt) (%) 51.97
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.07 vs. MRK: 51.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 43.35 Max: 105.49
Current: 51.97
10.88
105.49
Revenue Growth (3Y)(%) -3.30
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.5  Med: 2.3 Max: 21.4
Current: -3.3
-16.5
21.4
EBITDA Growth (3Y)(%) -6.40
MRK's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.30 vs. MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: -2 Max: 44.8
Current: -6.4
-17.6
44.8
EPS Growth (3Y)(%) -7.90
MRK's EPS Growth (3Y)(%) is ranked lower than
70% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.3  Med: 6.7 Max: 73.8
Current: -7.9
-29.3
73.8
» MRK's 10-Y Financials

Financials (Next Earnings Date: 2016-10-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
Robert Bruce 259,400 sh (unchged)
David Carlson 250,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Prem Watsa 12,000 sh (unchged)
David Dreman Sold Out
Kyle Bass Sold Out
Tom Russo Sold Out
RS Investment Management Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
Barrow, Hanley, Mewhinney & Strauss 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

Tom Russo 3,836 sh (New)
John Buckingham 24,665 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Jeremy Grantham 4,200 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

Richard Pzena 921,365 sh (New)
David Dreman 710 sh (New)
John Burbank 1,370,117 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
David Carlson 250,000 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Russo 3,836 sh (unchged)
NWQ Managers Sold Out
Jeremy Grantham Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Signature Select Canadian Fund 149,400 sh (-3.24%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
Q2 2016

MRK Guru Trades in Q2 2016

Tom Gayner 5,600 sh (New)
Jim Simons 2,926,534 sh (+504.24%)
Richard Pzena 1,415,390 sh (+53.62%)
Ray Dalio 251,546 sh (+19.36%)
Ken Fisher 6,759,345 sh (+0.91%)
Mairs and Power 102,164 sh (+0.31%)
Robert Bruce 259,400 sh (unchged)
David Dreman 710 sh (unchged)
David Carlson 250,000 sh (unchged)
Murray Stahl 45,497 sh (unchged)
Jeff Auxier 153,303 sh (unchged)
Tom Russo Sold Out
John Burbank Sold Out
Barrow, Hanley, Mewhinney & Strauss 26,516,070 sh (-0.55%)
Dodge & Cox 24,372,814 sh (-0.70%)
John Buckingham 25,676 sh (-0.81%)
PRIMECAP Management 2,967,700 sh (-0.84%)
Kahn Brothers 964,925 sh (-2.08%)
Pioneer Investments 901,916 sh (-2.54%)
Charles Brandes 2,891,914 sh (-3.60%)
Mario Gabelli 113,505 sh (-3.93%)
Vanguard Health Care Fund 46,499,820 sh (-4.57%)
Richard Snow 848,738 sh (-6.84%)
Ruane Cunniff 3,981 sh (-18.66%)
Manning & Napier Advisors, Inc 404,399 sh (-19.37%)
T Rowe Price Equity Income Fund 3,500,000 sh (-25.58%)
First Eagle Investment 7,790 sh (-51.58%)
Joel Greenblatt 540,222 sh (-56.73%)
Paul Tudor Jones 3,900 sh (-99.45%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:NVS, NYSE:PFE, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:BAYRY, OTCPK:SZUKF, OTCPK:ALPMY, OTCPK:OTSKF, NYSE:JNJ, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:MAYNF » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company's operations are managed on a products basis and are comprised of four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The Pharmaceutical segment is the only reportable segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, administered at physician offices. The Company sells these human health vaccines to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The Alliances segment includes results from the Company's relationship with AstraZeneca LP until the termination of that relationship on June 30, 2014. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Products within the Company's franchises are - Primary Care and Women's Health include Cardiovascular, Diabetes, and General Medicine and Women's Health; Hospital and Specialty include Hepatitis, HIV, Hospital Acute Care, and Immunology; Oncology includes Keytruda, Emend, Temodar, and Temodal; Diversified Brands includes Respiratory and Others; and Vaccines. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. Principal products in this segment include - Livestock Products; Poultry Products; Companion Animal Products; and Aquaculture Products. The Company's competitors include other research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers and animal health care companies.

Top Ranked Articles about Merck & Co Inc

Sanofi Sues Merck Over Patent Infringement Company trying to prevent further competition, reverse declining sales
French pharmaceutical giant Sanofi SA (NYSE:SNY) filed a lawsuit against Merck & Co. (NYSE:MRK) for supposed patent infringements last Friday. Read more...
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth A low-risk dividend for the short to mid term
From the price to sales point of view, Merck (NYSE:MRK) is one of the most expensive healthcare stocks, trading at nearly 4.5 times sales, more than you need to pay for Pfizer (NYSE:PFE) or Novartis (NYSE:NVS). Merck is possibly the only pharma major to see its stock price almost steadily rise in the last five years. It has more than doubled its price during that time, from under $30 in August 2011 to above $60 in August 2016. Read more...
Revenue and Earnings Higher for Merck in the Second Quarter Merck reports good second quarter results
Merck (NYSE:MRK) reported second quarter earnings on Friday, July 29. The Dow Jones Industrial Average component beat earnings estimates for both revenue and earnings per share. Revenue for the quarter was $9.84 billion, beating estimates by $60 million. Earnings per share for the quarter were 93 cents, beating estimates by 0.02 cents. Read more...
Merck CEO Sells 60,000 Company Shares Company's vice president sells 75,000 shares in 2 transactions
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 60,000 company shares at a per share price of $58.00 on July 5. The total transaction was $3.48 million. Read more...
Merck CEO Kenneth Frazier Sells 131,040 Shares Merck has 2 products recently approved by FDA
Kenneth Frazier (Insider Trades), CEO, president and chairman of Merck & Co. Inc. (MRK), sold 131,040 shares of the company on April 14. The average price per share was $56.11 for a total transaction cost of $7,352,654. Merck is a pharmaceuticals company that provides prescription medicines, vaccines, biologic therapies and animal health products worldwide. The company has a market cap of $155.49 billion and a P/S ratio of 3.97. Read more...
5 Guru Picks in Volatile Biotech Industry Johnson & Johnson and Merck each have the backing of more than 25 gurus
Biotech and pharmaceutical stocks made some of the biggest headlines this year, as 2015 saw massive waves of M&A activity, including the Pfizer (NYSE:PFE) and Allergan (NYSE:AGN) merger, the second-largest deal of all time valued at $160 billion. Other companies found themselves in the spotlight for less than desirable reasons, such as Valeant Pharmaceuticals (NYSE:VRX), whose stock has tanked in the past several months. Read more...
Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? The question that needs to be asked about AbbVie's demise is: What caused the earnings decline in the last five years after it went public?
Merck & Co. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV) are two very different companies and face very different situations when it comes to earnings and growth, not to mention one is significantly older than the other. From 2009 to 2010, Merck's earnings fell by 14 times what they previously were but have made a comeback and have leveled out while AbbVie has only been public since 2013 and in its short history as a public has seen its earnings plunge by 20.31% annually. Merck's earnings have stayed consistent since its earnings recovered from 26 cents in December 2010 to $3.74 currently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 34.81
MRK's P/E(ttm) is ranked lower than
60% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.52 vs. MRK: 34.81 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.33  Med: 20.23 Max: 138.33
Current: 34.81
6.33
138.33
Forward P/E 16.00
MRK's Forward P/E is ranked higher than
57% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.76 vs. MRK: 16.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.81
MRK's PE(NRI) is ranked lower than
60% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.50 vs. MRK: 34.81 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.33  Med: 20.23 Max: 138.33
Current: 34.81
6.33
138.33
Price/Owner Earnings (ttm) 22.92
MRK's Price/Owner Earnings (ttm) is ranked higher than
69% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.08 vs. MRK: 22.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.1  Med: 15.8 Max: 48.31
Current: 22.92
6.1
48.31
P/B 3.99
MRK's P/B is ranked lower than
62% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. MRK: 3.99 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.22 Max: 7.25
Current: 3.99
1.72
7.25
P/S 4.46
MRK's P/S is ranked lower than
65% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. MRK: 4.46 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.28 Max: 5.48
Current: 4.46
2.02
5.48
PFCF 18.25
MRK's PFCF is ranked higher than
63% of the 193 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.56 vs. MRK: 18.25 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 16.02 Max: 88.93
Current: 18.25
7.87
88.93
POCF 15.85
MRK's POCF is ranked higher than
55% of the 256 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. MRK: 15.85 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 13.31 Max: 35.85
Current: 15.85
6.67
35.85
EV-to-EBIT 26.63
MRK's EV-to-EBIT is ranked lower than
62% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.31 vs. MRK: 26.63 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.5 Max: 52.6
Current: 26.63
4.9
52.6
EV-to-EBITDA 14.09
MRK's EV-to-EBITDA is ranked higher than
62% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.21 vs. MRK: 14.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.6 Max: 20.4
Current: 14.09
4.2
20.4
PEG 3.78
MRK's PEG is ranked lower than
67% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. MRK: 3.78 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.52  Med: 2.73 Max: 28.55
Current: 3.78
0.52
28.55
Shiller P/E 27.94
MRK's Shiller P/E is ranked higher than
73% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.59 vs. MRK: 27.94 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 8.27  Med: 16.44 Max: 28.38
Current: 27.94
8.27
28.38
Current Ratio 1.87
MRK's Current Ratio is ranked lower than
61% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. MRK: 1.87 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.87
1.07
3.7
Quick Ratio 1.44
MRK's Quick Ratio is ranked lower than
62% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. MRK: 1.44 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.28 Max: 3.44
Current: 1.44
0.8
3.44
Days Inventory 131.92
MRK's Days Inventory is ranked lower than
58% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.00 vs. MRK: 131.92 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.16
Current: 131.92
104.23
205.16
Days Sales Outstanding 64.00
MRK's Days Sales Outstanding is ranked higher than
61% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.08 vs. MRK: 64.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 58.77 Max: 87.87
Current: 64
44.5
87.87
Days Payable 62.16
MRK's Days Payable is ranked lower than
56% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.81 vs. MRK: 62.16 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.81
Current: 62.16
30.2
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.92
MRK's Dividend Yield is ranked higher than
79% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.52 vs. MRK: 2.92 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.8 Max: 6.68
Current: 2.92
2.51
6.68
Dividend Payout 1.01
MRK's Dividend Payout is ranked lower than
80% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. MRK: 1.01 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.15  Med: 0.52 Max: 4.22
Current: 1.01
0.15
4.22
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
63% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.8 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 2.94
MRK's Forward Dividend Yield is ranked higher than
80% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. MRK: 2.94 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.53
MRK's Yield on cost (5-Year) is ranked higher than
72% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.04 vs. MRK: 3.53 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.56 Max: 8.01
Current: 3.53
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.1 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.11
MRK's Price/Tangible Book is ranked lower than
96% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. MRK: 33.11 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 33.11
3.19
3112.5
Price/Projected FCF 1.45
MRK's Price/Projected FCF is ranked higher than
74% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.65 vs. MRK: 1.45 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.45
0.75
3.04
Price/Median PS Value 1.36
MRK's Price/Median PS Value is ranked lower than
62% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. MRK: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.2 Max: 1.98
Current: 1.36
0.65
1.98
Price/Peter Lynch Fair Value 5.74
MRK's Price/Peter Lynch Fair Value is ranked lower than
92% of the 142 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. MRK: 5.74 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 1.64 Max: 10.48
Current: 5.74
0.55
10.48
Price/Graham Number 7.13
MRK's Price/Graham Number is ranked lower than
91% of the 400 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 7.13 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 3.93 Max: 31.92
Current: 7.13
1.09
31.92
Earnings Yield (Greenblatt) (%) 3.84
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. MRK: 3.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 6.9 Max: 20.6
Current: 3.84
1.9
20.6
Forward Rate of Return (Yacktman) (%) 10.83
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.64 vs. MRK: 10.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.8 Max: 22.2
Current: 10.83
-5.7
22.2

More Statistics

Revenue (TTM) (Mil) $39,444
EPS (TTM) $ 1.81
Beta0.73
Short Percentage of Float1.10%
52-Week Range $47.97 - 64.00
Shares Outstanding (Mil)2,765.21

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 39,576 39,750 40,887
EPS ($) 3.74 3.89 4.08
EPS w/o NRI ($) 3.74 3.89 4.08
EPS Growth Rate
(3Y to 5Y Estimate)
4.65%
Dividends Per Share ($) 1.82 1.86 1.85
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Investors Reward Merck Despite Flat Revenue Growth Sep 27 2016 
US Indexes Gain Ahead of Central Bank Announcements Sep 20 2016 
Sanofi Sues Merck Over Patent Infringement Sep 20 2016 
Stocks Trade Lower Monday With Global Central Bank Uncertainty Sep 19 2016 
Kahn Brothers Trims Pfizer, Citigroup Sep 16 2016 
US Market Indexes Mixed With Increased Uncertainty Sep 14 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
Slowing Economic Growth Has Stocks Trading Lower Sep 07 2016 
Volatile September Likely After August Losses Sep 06 2016 
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 

More From Other Websites
Merck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016 Sep 28 2016
MSD Animal Health Demonstrates Commitment to Eliminate Rabies Worldwide with Donation of More Than... Sep 28 2016
Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with... Sep 28 2016
6:46 am Merck announces 2 new trials of keytruda as monotherapy & in combination with chemotherapy... Sep 28 2016
Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with... Sep 28 2016
Blockbuster biotech deal coming? Sep 27 2016
Gilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck Sep 27 2016
Mylan’s Wheelhouse Impressive, Includes a New FDA Accepted Drug Sep 27 2016
Wall Street Sells Off on Worries Over Clinton-Trump Showdown Sep 26 2016
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies Sep 26 2016
[$$] Merck’s Keytruda Finds Fast Entry Into China Via Medical-Tourism Push Sep 23 2016
You’ve Heard about the EpiPen Debacle, but Have You Heard This? Sep 23 2016
[$$] Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push Sep 23 2016
Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25 Sep 23 2016
Gilead Sciences Focuses on a Strong Inorganic Growth Strategy Sep 23 2016
Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25 Sep 23 2016
Merck & Co., Inc. – Value Analysis (NYSE:MRK) : September 22, 2016 Sep 22 2016
How’s Gilead Sciences Expected to Perform in 2016? Sep 22 2016
Moves in Cancer Therapeutics among Recent Developments for Ionis Sep 22 2016
Merck Invests over € 50 million in Flagship Pharmaceutical Packaging Building in Darmstadt Sep 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)